BBC Broadcasts Interview with Dr. Samuel Stupp, Founder of Arrowhead Portfolio Company, Nanotope, Inc.

PASADENA, Calif.--(BUSINESS WIRE)-- An interview with Dr. Sam Stupp, founder and scientific advisor to Nanotope, Inc., an Arrowhead (NASDAQ: ARWR) portfolio company, was broadcast by the BBC World Service on November 28, 2010. In the interview, Dr. Stupp describes and discusses the regenerative medicine platform being developed by Nanotope, as well as nanotechnology and regenerative medicine in general.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies, Nanotope, Inc. and Leonardo Biosystems, Inc.



CONTACT:

The Piacente Group
Brandi Floberg, 212-481-2050

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Technology  Nanotechnology  Health  Biotechnology  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.